Franca N Alaribe,
Staffania Maniero,
Cecilia Pancaldi 
For correspondence:- Cecilia Pancaldi Email: ceciliapancaldi@unife.it
Received: 7 April 2010 Accepted: 8 October 2010 Published: 23 December 2010
Citation: Alaribe FN, Maniero S, Pancaldi C. Malignant Pleural Mesothelioma Prognostic Marker: A Review of Osteopontin and Soluble Mesothelin Peptides. Trop J Pharm Res 2010; 9(6):605-613 doi: 10.4314/tjpr.v9i6.12
© 2010 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
This article is a review of a series of three studies that proved the involvement of osteopontin as a prognostic marker in malignant pleural mesothelioma (MPM) cancers. The approach used involved synthesizing and analysing the three articles. The first proves the utilization of osteopontin and mesothelin for diagnostic and prognostic assessment of MPM in patients previously exposed to asbestos and those with pleural metastasis. The second proves that immunohistochemical analysis identified osteopontin to have a prognostic role from its ex
Fulltext in PDF